|
The ENHANCE study is an international 2-year, randomized, double-blind, controlled trial designed to test the hypothesis that treatment of hypercholesterolemia by use of 2 complementary agents, ... The ENHANCE trial uses novel state-of-the-art single-frame digital image acquisition and rigorous quality assurance and control.
|
www.medscape.com/medline/abstract/15846260
|
|
|
|
Original Article from The New England Journal of Medicine -- Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia ... A correction has been published: N Engl J Med 2008;358(18):1977. ... Of these patients, 64 in the simvastatin-only group and 41 in the combined-therapy group did not complete the trial.
|
content.nejm.org/cgi/content/full/358/14/1431
|
|
|
The ENHANCE trial, designed to show that lowering cholesterol with Vytorin works better than lowering cholesterol with a statin, did not turn out the way the designers had hoped. ... The ENHANCE Trial and What It Means...
|
heartdisease.about.com/od/cholesteroltriglycerides/a/EN...
heartdisease.about.com/od/cholesteroltriglycerides/a/ENHANCE.htm
|
|
Today, Merck and Schering-Plough finally released results from the ENHANCE trial, a controversial study comparing a statin drug (simvastatin) to the widely advertised anti-cholesterol drug Vytorin (which consists of simvastatin plus ezetimbe, a drug that blocks cholesterol absorption from the gut).
|
heartdisease.about.com/b/2008/01/14/enhance-at-best-no-...
heartdisease.about.com/b/2008/01/14/enhance-at-best-no-benefit-from-vytorin-or-zetia.htm
|
|
THE MERCK MANUALS ... Dec. 1, 2009 ... U.S. Department of Health & Human Services Recommends Merck's First-in-Class Integrase Inhibitor ISENTRESS® (raltegravir) Tablets, in Combination Therapy, as a Preferred Regimen for Treatment-Naïve Patients with HIV-1 Infection...
|
www.sch-plough.com/schering_plough/news/release.jsp?rel...
www.sch-plough.com/schering_plough/news/release.jsp?releaseID=1095943
|
|
The ENHANCE trial is a multinational, randomized, double-blind, trial that examines the effects of the highest approved dose of VYTORIN/INEGY versus the highest approved dose of simvastatin 80 mg alone in patients with Heterozygous Familial Hypercholesterolemia (HeFH).
|
www.medicalnewstoday.com/articles/96149.php
|
|
We were implored by some to mention this statement over anger at the ACC presentation last week of the Enhance trial, which found Vytorin failed to show any benefit over the much cheaper Zocor in reducing plaque in the carotid artery, and even showed a statistically insignificant buildup, although it did a better job...
|
www.pharmalot.com/2008/04/did-the-enhance-trial-enhance...
www.pharmalot.com/2008/04/did-the-enhance-trial-enhance-anything/
|
|
Since JFS has covered the ENHANCE trial extensively, there’s no need to rehash it, but the discussions among cardiologists might be of interest. ... The [arterial thicknesses] difference is so small as to be unimportant, says John Kastelein, the University of the Netherlands doctor who led the trial. "This is a zero...
|
junkfoodscience.blogspot.com/2008/03/enhance-trial-publ...
junkfoodscience.blogspot.com/2008/03/enhance-trial-published-today.html
|
|
UPDATED // If the treatment effect was nil, would the blinded data from ENHANCE have foretold the results of the surrogate-end-point trial? Some imaging experts say yes, but Schering-Plough says no, telling heartwire that the blinded data gave no indication of the trial's eventual outcome. ... ENHANCE saga continues:
|
www.theheart.org/article/840879.do
|
|
